Introduction
Prenatal diagnosis is the process checking for the presence of disease or condition in a fetus or embryo before birth, including congenital birth defects, genetic disorders, and chromosome abnormalities. According to a recent Korean national statistics report, congenital birth defects occur in about 3% of the total newborns, and about 20% of congenital malformations in children are due to chromosomal abnormality [1, 2] . Among Prenatal diagnostic methods to confirm fetal chromosomal abnormalities are carried out in an invasive way. There are several methods specialized for certain periods of pregnancy, including chorionic villi sampling (CVS), amniocentesis, and cordocentesis, which are performed at 10-12 weeks [10] [11] [12] , 15-20 weeks [13, 14] , and 18-20 weeks [15] of pregnancy, respectively. Although those invasive tests are required to confirm the positive prenatal screening test, confirmatory tests carry related risks of maternal and fetal complication, including fetal loss.
To reduce the invasive confirmatory procedures, more accurate and less invasive prenatal screening tests have been developed. Lo et al. [16] reported in 1997 that fetal cell-free DNA (cfDNA) is present in maternal blood. With the advances in experimental technologies, it has been possible to coextract the fetal compartment of cfDNA in maternal plasma and to measure the amount of fetal cell-free nucleic acids according to the gene dosage.
Recently, NIPT with next-generation sequencing (NGS), which uses fetal cfDNA from maternal blood, has been adopted as a primary screening test for fetal chromosomal aneuploidy. NGS-based NIPT has been reported to have >99% sensitivity and specificity in detecting trisomy 21 (T21). In addition, the positive predictive value of NGS-based NIPT for screening T21 is around 80% in the general population. NIPT will contribute to decreasing the need for unnecessary invasive procedures, including amniocentesis and CVS, for confirming fetal aneuploidy. However, NGS has several limitations. First, it is more expensive than the current antenatal screening protocol, which could hinder the adoption of this innovative technique in clinical practice. Second, there is a risk of screening failure due to the limited amount of fetal DNA fraction for analysis. Third, NGS is time consuming-it requires 1 week before results are obtained.
Digital polymerase chain reaction (dPCR) is a novel approach for detecting and quantifying nucleic acid. dPCR provides realtime diagnostic advantages with higher sensitivity, accuracy, and absolute quantification than conventional quantitative PCR. It has been suggested that dPCR will decrease the cost by targeting specific sequences in the target chromosome, and dPCR-based noninvasive testing will facilitate progress toward the implementation of a noninvasive approach for screening for T21, T18 and T13.
Digital PCR
The dPCR is a novel method for the precise quantification of nucleic acid. Conventional PCR is referred to as the first generation of PCR. The first-generation PCR allows qualitative analysis by using agarose gel electrophoresis. However, quantitative analysis with conventional PCR is difficult. To complement the disadvantage of conventional PCR in quantitative analysis, the second generation of PCR, quantitative PCR (qPCR, real-time PCR) was introduced. The qPCR allows quantitative and qualitative analyses of target genes by monitoring the amplification of a targeted DNA molecule during PCR. However, qPCR has disadvantages such as varying results depending on PCR efficiency. dPCR is a new application for the detection and quantitative analysis of nucleic acids [17] . The concept of dPCR was introduced to overcome the limitation of qPCR. Unlike the relative analysis of qPCR that needs a standard curve for the measurement of target molecules, dPCR incorporates absolute quantification by counting the total number of target molecules in a digital format. It allows a more sensitive detection and accurate quantitative analysis of the target nucleic acid molecules [18] [19] [20] [21] .
In the dPCR procedure, the template DNA is diluted and divided into a large number of reaction compartments, allowing one target molecule to be located per two reaction compartments [22] . With the successful distribution of target molecules, positive amplification signals in each compartment reflect the amplification of a single target molecule. In consequence, absolute quantification of a target molecule can be applied in a digital format by counting each reaction compartment as either "1" or "0" for positive or negative signal, respectively. Analyzing the proportion of the "1" signal out of the total reactions, the concentration of the nondiluted original target molecule can be estimated. Increasing the number of reaction compartments improves the precision of quantification, thus enabling the resolution of small concentration differences [23] .
There are two different platforms for dPCR; a droplet-based and a chip-based technique. Between the two platforms, the droplet-based approach has four steps for a stable experiment. Those steps consist in droplet formation, PCR reaction for each droplet, followed by droplet reading and result analysis. Once the droplet is formed, each droplet acts as a single well so that the PCR reaction occurs independently in each droplet. The chip-based platform consists in reaction preparation and automatic loading of the reaction mixture to the chip where the PCR reaction will be carried out in each well of the chip plate. The amplified reaction is then analyzed by counting the wells, followed by statistical analysis. On the basis of the results of analysis, it can be applied to various methods (Fig. 1) .
Newly emerging dPCR areas have targeted a relatively small segment of the market [24] . However, the annual growth rate of dPCR technology is projected to increase to 52%, and its excellence has been verified during the introductory period. The market demand is increasing steadily as new applications, such as rare mutation detection and NIPT, are consistently suggested. Bio-Rad, Fluidigm, Life Technology, and Rain Dance Technologies entered the field of dPCR market in 2012 (Table 2) . Moreover, many companies performing qPCR-based techniques and manufacturing qPCR equipment are relatively active. However, with the high price reaching 136,000 US dollars (USD), the wide use of such installations is difficult to expect, especially with the impact of economic recession [25] .
NIPT and dPCR
As we described previously, it is necessary to develop a method for prenatal chromosome screening that can reduce the risk to the fetus related to the confirmatory procedure. Such a method should have relatively simple experimental requirements at a reasonable cost. Various types of NGS methods are being developed for NIPT [26, 27] . The NIPT approach with dPCR may provide comparable sensitivity and specificity at a reduced cost. This novel technique will contribute to making NIPT the primary screening test in the future (Table 3) .
NIPT for the fetal aneuploidy requires technologies that provide stable, error-free, and secure information without losing genetic information of a fetal gene present in small amount in the pregnant woman's blood plasma. However, cfDNA analysis without any knowledge of the percentage of the fetal genetic material present in the blood or plasma of a pregnant woman can present problems with the reliability of results [28] . Separating fetal-derived genes to the complete exclusion of maternal-derived genes that are present in large amounts in the blood of pregnant women has technical difficulties and cost issues. Furthermore, in the course of amplifying the sample of blood or plasma of pregnant women, background signals due to the amplification of maternal-derived gene lead to a low reliability of the analysis of fetal-derived genes, and are likely to represent false-positive results [29] . Individual institutions incur high expenses for tests and experience difficulties in the interpretation of results.
Lo et al. [30] introduced dPCR for screening fetal T21 in 2007. The authors demonstrated the feasibility of dPCR in determining the allelic imbalance of a single nucleotide polymorphism in PLAC4 mRNA of chromosome 21. In addition, they detected T21 prenatally by using a nonpolymorphism-based approach with dPCR. However, the sample that the authors used contained 25% of fetal DNA in maternal plasma, which was a relatively large amount. Fan et al. [31] applied microfluidic dPCR to diagnose fetal aneuploidy prenatally. By applying 12,765 digital array microfluidic chips, dPCR analysis accurately identified all fetal aneuploidies in the analyzed samples. In 2009, the estimated cost was only 400 USD. Although the authors used amniotic fluid and CVS samples for the study, they suggested NIPT with dPCR as an attractive tool for prenatal diagnosis because of its robustness and simplicity. Evans et al. [32] conducted power analysis. The authors developed a power equation and calculated the number of wells that were important for the experimental cost. With the model that was adopted in the study, 2,609 wells would be sufficient to achieve a 99% detection rate with a 1% false-positive rate. The authors demonstrated that dPCR is a potentially cheaper method for the diagnosis of T21. dPCR has been adopted not only for the diagnosis of fetal aneuploidy but also for fetal rhesus D (RHD) genotyping, paternal CFTR (cystic fibrosis transmembrane conductance regulator) mutation, and fetal hemophilia, which is a bleeding disorder with X-linked inheritance and fetal RHD genotyping [33] [34] [35] [36] . dPCR showed greater sensitivity than qPCR in identifying fetal sex and in RHD genotyping [37] .
One of other genetic applications of dPCR is gene expression analysis, such as regulatory RNA molecules affecting basic cellular processes by microRNA [38] . The sensitivity of dPCR enables the detection of the methylation pattern in pathological states of pregnancy [39] . Moreover, gene copy number alterations and rare allele detection were also achieved by using dPCR [40] . dPCR is expected to satisfy the demand for prenatal screening with its accurate test results and relatively cheap cost. Moreover, it has a different competitive power from NGS as an early screening technology that can select patients who need further amniotic fluid testing. Because of the increasing demands for reduced experimental costs, NIPT with dPCR has attracted attention. Compared with NIPT with NGS, NIPT with dPCR would be more cost-effective and less time consuming.
Many NGS methods are being developed for noninvasive prenatal chromosomal screening; however, although these methods need a separate technique for diagnosis, there are limitations in performing these tests in individual hospitals owing to the high costs and difficulty in interpreting the results. Through its many advantages of real-time diagnosis, high sensitivity, and digitization of test results, dPCR has made it possible to develop a variety of diagnostic technologies without the use of a sequencing method.
NIPT with dPCR has several limitations. Unlike NIPT with NGS, the specific target detection of dPCR uses a single probe set; therefore, the sensitivity of each target detection has to be validated individually, which also limits the provision of big data for large-scale analysis. Moreover, unlike NGS, the dPCR approach cannot detect low-grade mosaicism. Furthermore, it is unable to detect chromosomal structural abnormalities such as balanced translocation. Lastly, there are few reports that demonstrate the feasibility of dPCR for detecting fetal aneuploidy antenatally.
Further studies on NIPT with dPCR as an ancillary diagnostic screening tool but not as a substituent, which could aid in increasing the detection rate of NIPT, are being actively performed. Recently, the cost of ancillary diagnosis is expected to be lowered by increasing the number of samples that need to be applied simultaneously, as well as through the development of the dPCR technique (Fig. 2) .
Future Perspective
Studies on noninvasive prenatal screening with dPCR, which can quantitatively analyze a very small amount of nucleic acid, involve collecting and analyzing characteristic genetic information from fetal genetic material existing in small amounts in maternal blood and serum.Through these studies, it is anticipated that the method can be applied not only in noninvasive prenatal chromosomal screening but also in the early diagnosis of genetic diseases caused by abnormalities in gene copy number (microdeletions and repetitions). Moreover, by analyzing characteristic fetal gene markers, it is expected that the problem of being unable to detect numerical abnormalities in sparse fetal target genes, due to the abundant background maternal genetic signals when performing dPCR, can be solved. Therefore, through its simple technological applicability, relatively cheap cost, and accurate test results, dPCR is anticipated to be able to replace NGS methods, which are costly and difficult to interpret. Finally, the development of a technology that has great socioeconomic impact can be successfully achieved.
dPCR symbolizes the synergy that results from research in combined academic fields that create new knowledge and compensates for gaps in individual academic areas. The basic technology is helpful for developing noninvasive methods that can replace invasive methods such as amniocentesis, and that can greatly reduce the risk to the mother and fetus. The large processing capability of dPCR is consistent with the need for a lowered sample volume or simultaneous multiple target detection in prenatal diagnostic screenings. It provides accurate diagnostic information, improves the patients' clinical outcome, and reduces patient management costs. Significant biomarkers can be identified through the development of the noninvasive prenatal screening method of maternal peripheral blood with dPCR, as an ancillary screening before the precise diagnosis. Ultimately, we expect that this method can help mitigate the national health expenditure for patient welfare by preventing unnecessary diagnostic costs. However, there are few studies that evaluate the feasibility of dPCR in detecting fetal aneuploidy. In addition, the cost-effectiveness of dPCR for NIPT should be demonstrated. Further studies are warranted to evaluate the feasibility and cost-effectiveness of the dPCR approach for NIPT.
